FDA warns against one-dose regimen for coronavirus vaccines: Report


Scientists at the US Food and Drug Administration (FDA) are strongly against administering only single doses of the Moderna and Pfizer vaccines, as their efficacy has only been proven if people get two shots, The Wall Street Journal reports.

“It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death,” Peter Marks, director of the FDA center that oversees vaccines, told The Wall Street Journal on Saturday.

In February, some scientists and lawmakers suggested using a one-dose regimen for all vaccines approved in the US, after certain preliminary studies showed that a single shot could be enough for some people.

“You would be flying blind to just use one dose,” a senior scientist and adviser to US President Joe Biden told The Wall Street Journal, adding “If you’re going to do something else other than follow the studies shown to the FDA, show me that this one-shot effect is durable.”

At the end of February, the FDA announced that it had given emergency use authorization to Johnson & Johnson’s single-shot vaccine. The vaccine was the third candidate to be given FDA approval, following authorization for two-shot vaccines produced by Pfizer and Moderna.

Biden said after the approval of Johnson & Johnson’s vaccine that things were still likely to get worse in terms of COVID-19 in the US as new variants emerge.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor


Show More

Related Articles

Back to top button